Renovaro Inc
RENB1.420USD
0.000
Close 11/07, 16:00（ET）Quotes delayed by 15 min
251.90MMarket Cap
LossP/E TTM
More Details of Renovaro Inc Company
Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Renovaro Inc Info
Ticker SymbolRENB
Company nameRenovaro Inc
IPO dateNov 18, 2014
CEOMr. David Weinstein
Number of employees25
Security typeOrdinary Share
Fiscal year-endNov 18
Address2080 Century Park East, Suite 906
CityLOS ANGELES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code90067
Phone14539179840
Website
Ticker SymbolRENB
IPO dateNov 18, 2014
CEOMr. David Weinstein
Company Executives of Renovaro Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gumrukcu (Serhat)
53.66%
William (Anderson Wittekind)
20.94%
RS Group ApS
15.27%
Lakysa Ventures, Inc
9.78%
PasecoApS
6.24%
Shareholders
Shareholders
Proportion
Gumrukcu (Serhat)
53.66%
William (Anderson Wittekind)
20.94%
RS Group ApS
15.27%
Lakysa Ventures, Inc
9.78%
PasecoApS
6.24%
Shareholder Types
Shareholders
Proportion
Individual Investor
75.44%
Corporation
34.91%
Investment Advisor
9.40%
Hedge Fund
1.15%
Investment Advisor/Hedge Fund
0.90%
Research Firm
0.66%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
144
2.80M
12.10%
+455.32K
2025Q2
156
65.41M
35.65%
+4.54M
2025Q1
161
103.48M
60.94%
+42.30M
2024Q4
155
103.71M
63.86%
+49.62M
2024Q3
149
51.49M
35.21%
-1.80M
2024Q2
151
51.88M
36.43%
+6.39M
2024Q1
154
44.98M
32.23%
+3.81M
2023Q4
151
44.01M
67.51%
+217.77K
2023Q3
146
41.12M
71.08%
+1.11M
2023Q2
147
41.48M
71.99%
+3.87M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gumrukcu (Serhat)
1.25M
5.4%
--
--
Jul 15, 2025
William (Anderson Wittekind)
476.63K
2.06%
--
--
Jul 15, 2025
RS Group ApS
1.68M
7.26%
+322.24K
+23.69%
Jul 15, 2025
Lakysa Ventures, Inc
2.15M
9.27%
+2.15M
--
Jul 15, 2025
PasecoApS
2.70M
11.65%
+1.44M
+113.93%
Jul 15, 2025
BMO Nesbitt Burns Inc.
1.36M
5.86%
+1.36M
--
Jul 15, 2025
Weird Science LLC
84.03K
0.36%
--
--
Jul 15, 2025
The Vanguard Group, Inc.
492.46K
2.12%
-73.57K
-13.00%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
256.55K
1.11%
-424.73K
-62.34%
Jun 30, 2025
Millennium Management LLC
214.96K
0.93%
+213.51K
+14684.25%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
